Almac has Successful MHRA Inspection at its Clinical Services UK Site
Almac
is pleased to announce the successful completion of an inspection of its Clinical Services UK facility located in Craigavon by the Medicines and Healthcare products Regulatory Agency (MHRA)
The routine inspection which took place over four days, from September 13th-September 16th, was conducted by a MHRA inspector who concluded that the site continues to be compliant with EU Good Manufacturing Practices, with no critical or major failures observed.
Commenting on the inspection Paul O’Connor (Vice President, Quality), said:
“We are extremely pleased with the outcome of our inspection. These successful results are a positive reflection of all the investment Almac has made over the past few years in our facilities and recruitment of the best employees. ”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
